Overcoming resistance to PARP inhibitions is an area of unmet need in ovarian cancer. Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, speaks on the importance of elucidating the mechanisms of PARP inhibiton resistance in ovarian cancer, and its importance in terms of improving patient stratification for therapeutic strategies. This interview took place at the ESMO Gynaecological Cancers Virtual Congress 2021.
